ClinVar Miner

Submissions for variant NM_000384.3(APOB):c.13028_13029del (p.Tyr4343fs)

dbSNP: rs760832994
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Revvity Omics, Revvity RCV001785651 SCV002021416 likely pathogenic not provided 2022-12-13 criteria provided, single submitter clinical testing
GeneDx RCV001785651 SCV002526180 likely pathogenic not provided 2023-07-25 criteria provided, single submitter clinical testing Observed in an individual with familial hypercholesterolemia (Al-Khateeb et al., 2013); however, patient-specific details were not provided and some individuals from this cohort harbored additional variants in the LDLR gene; Not observed at significant frequency in large population cohorts (gnomAD); Frameshift variant predicted to result in protein truncation, as the last 221 amino acids are replaced with 2 different amino acids, and other loss-of-function variants have been reported downstream in HGMD.; This variant is associated with the following publications: (PMID: 23775634, 36499307, 32009526)
Ambry Genetics RCV002383985 SCV002692494 uncertain significance Cardiovascular phenotype 2023-03-21 criteria provided, single submitter clinical testing Not expected to trigger nonsense-mediated mRNA decay Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.
New York Genome Center RCV002467842 SCV002764567 uncertain significance Hypercholesterolemia, autosomal dominant, type B; Familial hypobetalipoproteinemia 1 2021-01-25 criteria provided, single submitter clinical testing The c.13028_13029del, p.Tyr4343CysfsTer3 variant identified in the APOB gene has been reported in an individual affected with a mild hypercholesterolemia [PMID:23775634]. This variant causing a frameshift at codon 4343 and a premature translational stop signal three amino acids downstream and the mutant mRNA may escape nonsense-mediated decay and may be expressed as a truncated protein that lacks the last 238 amino acids from the C-terminal end. This variant is found with low frequency in gnomAD v3.1 (1 heterozygotes, 0 homozygotes; allele frequency: 0.0006%) suggesting it is not a common benign variant in the populations represented in that database. Based on available evidence the c.13028_13029del, p.Tyr4343CysfsTer3 variant identified in the APOB gene is reported as a Variant of uncertain significance.
Invitae RCV002467842 SCV003305305 uncertain significance Hypercholesterolemia, autosomal dominant, type B; Familial hypobetalipoproteinemia 1 2022-07-21 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Tyr4343Cysfs*3) in the APOB gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 221 amino acid(s) of the APOB protein. This variant is present in population databases (rs760832994, gnomAD 0.02%). This premature translational stop signal has been observed in individual(s) with familial hypercholesterolemia (PMID: 23775634). ClinVar contains an entry for this variant (Variation ID: 440513). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV003479145 SCV004222742 uncertain significance not specified 2023-11-16 criteria provided, single submitter clinical testing Variant summary: APOB c.13028_13029delAT (p.Tyr4343CysfsX3) results in a premature termination codon, predicted to cause a truncation of the encoded protein, however, nonsense mediated decay is not expected. The variant allele was found at a frequency of 1.2e-05 in 242432 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.13028_13029delAT has been reported in the literature in individuals affected with Familial Hypercholesterolemia (Al-Khateeb_2013, Martin_2022). These reports do not provide unequivocal conclusions about association of the variant with Familial Hypercholesterolemia. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Five submitters have cited clinical-significance assessments for this variant to ClinVar after 2014 and classified as VUS (n=3) and likely pathogenic (n=2). Based on the evidence outlined above, the variant was classified as uncertain significance.
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV001785651 SCV004562377 uncertain significance not provided 2023-11-14 criteria provided, single submitter clinical testing The APOB c.13028_13029del; p.Tyr4343CysfsTer3 variant (rs760832994) is reported in the literature in individuals from hyperlipidemia cohorts, however patient-specific details are limited and in one cohort some individuals also carried additional variants in the LDLR gene (Al-Khateeb 2013, Pottinger 2020, Razman 2022). The c.13028_13029del variant is reported in ClinVar (Variation ID: 440513). It is observed in the general population with an overall allele frequency of 0.0015% (4/273834 alleles) in the Genome Aggregation Database (v2.1.1). This variant results in a premature termination codon in the last exon of the APOB gene. While this may not lead to nonsense-mediated decay, it is expected to create a truncated APOB protein removing just under 5% of the protein. Due to limited information, the clinical significance of this variant is uncertain at this time. References: Al-Khateeb AR et al. Molecular description of familial defective APOB-100 in Malaysia. Biochem Genet. 2013 Oct;51(9-10):811-23. PMID: 23775634. Pottinger TD et al. Pathogenic and Uncertain Genetic Variants Have Clinical Cardiac Correlates in Diverse Biobank Participants. J Am Heart Assoc. 2020 Feb 4;9(3):e013808. PMID: 32009526. Razman AZ et al. Genetic Spectrum of Familial Hypercholesterolaemia in the Malaysian Community: Identification of Pathogenic Gene Variants Using Targeted Next-Generation Sequencing. Int J Mol Sci. 2022 Nov 29;23(23):14971. PMID: 36499307.
PreventionGenetics, part of Exact Sciences RCV004541593 SCV004758782 likely pathogenic APOB-related disorder 2024-01-30 criteria provided, single submitter clinical testing The APOB c.13028_13029delAT variant is predicted to result in a frameshift and premature protein termination (p.Tyr4343Cysfs*3). This variant has been reported in individuals with familial hypercholesterolemia (Al-Khateeb et al. 2013. PubMed ID: 23775634; Razman et al. 2022. PubMed ID: 36499307). This variant is reported in 0.015% of alleles in individuals of East Asian descent in gnomAD. In ClinVar, this variant has conflicting interpretations of uncertain significance and likely pathogenic (https://www.ncbi.nlm.nih.gov/clinvar/variation/440513/). Frameshift variants in APOB are expected to be pathogenic. This variant is interpreted as likely pathogenic.
Laboratorium voor Moleculaire Diagnostiek Experimentele Vasculaire Geneeskunde, Academisch Medisch Centrum RCV000508887 SCV000605950 pathogenic Hypercholesterolemia, familial, 1 no assertion criteria provided research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.